Shares of BioAge Labs, Inc. (NASDAQ:BIOA – Get Free Report) were up 2.7% on Monday . The company traded as high as $5.10 and last traded at $4.93. Approximately 166,433 shares changed hands during mid-day trading, an increase of 30% from the average daily volume of 127,817 shares. The stock had previously closed at $4.80.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen cut BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, June 29th.
Get Our Latest Stock Analysis on BIOA
BioAge Labs Price Performance
BioAge Labs (NASDAQ:BIOA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.04).
Institutional Trading of BioAge Labs
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BIOA. Police & Firemen s Retirement System of New Jersey purchased a new stake in BioAge Labs during the 2nd quarter worth about $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after purchasing an additional 5,976 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in BioAge Labs during the 2nd quarter worth about $57,000. Intech Investment Management LLC purchased a new stake in BioAge Labs during the 2nd quarter worth about $60,000. Finally, Walleye Capital LLC purchased a new stake in BioAge Labs during the 2nd quarter worth about $64,000.
BioAge Labs Company Profile
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.
Further Reading
- Five stocks we like better than BioAge Labs
- How to Buy Gold Stock and Invest in Gold
- 3 Healthcare Pathbreakers With Long-Term Tailwinds
- What is the S&P/TSX Index?
- 3 Tariff-Proof Retailers Making New All-time Highs
- Overbought Stocks Explained: Should You Trade Them?
- With Shares Near Highs, Here’s to Watch in Broadcom’s Q3 Report
Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.
